menu
    • menu
    [{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"RLY-1971","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"GDC-6036","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.80000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.80000000000000004,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Relay Therapeutics \/ Relay Therapeutics"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RLY-2608","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RLY-4008","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Elevar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RLY-2608","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Relay Therapeutics

    Menu

    Relay Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Announces Updated Data for RLY-2608 + Fulvestrant in Progression-Free Survival

                            Details : RLY-2608 is a PI3K alpha inhibitor, small molecule, which is being evaluated for the treatment of patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2024

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Elevar Therapeutics

                            Deal Size : $500.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Elevar & Relay Therapeutics License Lirafugratinib for FGFR2 Cancer & Solid Tumors

                            Details : The agreement grants Elevar worldwide rights to develop and commercialize RLY-4008 (lirafugratinib), an oral small molecule inhibitor of FGFR2 being developed for FGFR2-driven cholangiocarcinoma.

                            Product Name : RLY-4008

                            Product Type : Small molecule

                            Upfront Cash : $75.0 million

                            December 03, 2024

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Elevar Therapeutics

                            Deal Size : $500.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Pricing of Public Offering of Common Stock

                            Details : The net proceeds from the offering will be used for research & development of the Company’s lead product, including RLY-4008 for the treatment of FGFR2-mutated Cholangiocarcinoma and other neoplasms.

                            Product Name : RLY-4008

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Positive Interim Data for RLY-2608 in Cancer Treatment

                            Details : RLY-2608 is a PI3K alpha inhibitor, small molecule, which is being evaluated for the treatment of patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                            Product Name : RLY-2608

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Proposed Public Offering of Common Stock

                            Details : The net proceeds from the offering will be used for research & development of the Company’s lead product, including RLY-4008 for the treatment of FGFR2-mutated Cholangiocarcinoma and other neoplasms.

                            Product Name : RLY-4008

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial

                            Details : The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                            Product Name : RLY-2608

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Nextech

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces $30 Million Private Placement Financing

                            Details : Relay Therapeutics expects to use net proceeds to advance RLY-2608, , a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia.

                            Product Name : RLY-2608

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : RLY-2608,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Nextech

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : X-Chem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            X-Chem Announces Achievement of Collaboration Milestone

                            Details : Under the collaboration, Relay Therapeutics utilized X-Chem’s DNA-Encoded Library platform to perform hit finding intended to discover molecules with differentiated pharmacological properties.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : X-Chem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Mul...

                            Details : RLY-4008 (lirafugratinib) is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers and demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in ...

                            Product Name : RLY-4008

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

                            Details : RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers and demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in in vivo models.

                            Product Name : RLY-4008

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : RLY-4008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth